Jazz Pharmaceuticals announced that the United States Centers for Medicare and Medicaid Services granted approval for a New Technology Add-on Payment for Vyxeos liposome for injection for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes, a rapidly progressing and life-threatening blood cancer. The Vyxeos NTAP will support Medicare beneficiaries’ access to Vyxeos when they are treated in certain inpatient hospital settings. The NTAP payment is in addition to the diagnosis-related group-based reimbursement that hospitals receive under the Medicare Hospital Inpatient Prospective Payment System. The NTAP designation is expected to remain in effect for a period of two to three years until the cost of Vyxeos is included in CMS’s recalibration of the DRG payment rate. The NTAP program is only available to new technologies meeting the definition of newness of the technology, exceeding cost criterion thresholds and demonstrating substantial clinical improvement over existing therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.